Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HLS Therapeutics, Inc.

http://www.hlstherapeutics.com/

Latest From HLS Therapeutics, Inc.

Galapagos Keeps Analysts Guessing About Future Plans

Analysts are scratching their heads over what direction the Belgian biotech will take in the coming months and years, with all eyes on an R&D day in October.

Sales & Earnings Clinical Trials

Dealmaking Quarterly Statistics, Q2 2022

During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.

Commercial Deals

Galapagos Enters Cancer Field With CellPoint Buy

Deal Snapshot: CEO Stoffels delivered on a recent promise to bring in mid-stage assets, acquiring a firm with a Phase I/IIa CAR-T therapy program for €125m ($131.6m) up front.

Deals Cancer

Clozapine REMS Program Paused After Problems With Re-Certification

US FDA says pharmacists may dispense the antipsychotic without a REMS authorization and wholesalers may continue to ship it during temporary suspension of REMS. A high call volume and long wait times have impacted patient access since the modified REMS launched on 15 November.

Risk Management Drug Review
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
UsernamePublicRestriction

Register